NeuroDerm Announces Eligibility for European Union Centralized Procedure for ND0612H


(August 6, 2014) - NeuroDerm announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure. ND0612H is a high-dose form of liquid LD/CD drug delivered continuously through subcutaneous administration by a belt pump. ND0612H is designed to significantly reduce motor complications in advanced Parkinson's disease patients. PUW funds have partially supported this research through a grant provided by The Michael J. Fox Foundation for Parkinson’s Research. Read more…

Click for a printer friendly version

Back to top